JP2023540618A5 - - Google Patents
Info
- Publication number
- JP2023540618A5 JP2023540618A5 JP2023516079A JP2023516079A JP2023540618A5 JP 2023540618 A5 JP2023540618 A5 JP 2023540618A5 JP 2023516079 A JP2023516079 A JP 2023516079A JP 2023516079 A JP2023516079 A JP 2023516079A JP 2023540618 A5 JP2023540618 A5 JP 2023540618A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- chain variable
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063077233P | 2020-09-11 | 2020-09-11 | |
| US63/077,233 | 2020-09-11 | ||
| PCT/EP2021/075012 WO2022053652A1 (en) | 2020-09-11 | 2021-09-10 | Combination therapy for cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023540618A JP2023540618A (ja) | 2023-09-25 |
| JP2023540618A5 true JP2023540618A5 (enExample) | 2024-09-17 |
Family
ID=78073883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023516079A Pending JP2023540618A (ja) | 2020-09-11 | 2021-09-10 | 癌の併用療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230364230A1 (enExample) |
| EP (1) | EP4211168A1 (enExample) |
| JP (1) | JP2023540618A (enExample) |
| KR (1) | KR20230066586A (enExample) |
| CN (1) | CN116601171A (enExample) |
| AU (1) | AU2021339005A1 (enExample) |
| CA (1) | CA3191282A1 (enExample) |
| IL (1) | IL301048A (enExample) |
| MX (1) | MX2023002852A (enExample) |
| WO (1) | WO2022053652A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026022712A1 (en) * | 2024-07-23 | 2026-01-29 | Sanofi | Cereblon ligase modulator and bcma nk cell engager combination therapy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008337517B2 (en) | 2007-12-14 | 2014-06-26 | Novo Nordisk A/S | Antibodies against human NKG2D and uses thereof |
| WO2010017103A2 (en) | 2008-08-04 | 2010-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Fully human anti-human nkg2d monoclonal antibodies |
| PL3202460T3 (pl) | 2010-02-11 | 2019-12-31 | Celgene Corporation | Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania |
| EP3833392A4 (en) * | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE |
-
2021
- 2021-09-10 WO PCT/EP2021/075012 patent/WO2022053652A1/en not_active Ceased
- 2021-09-10 IL IL301048A patent/IL301048A/en unknown
- 2021-09-10 CA CA3191282A patent/CA3191282A1/en active Pending
- 2021-09-10 EP EP21786092.3A patent/EP4211168A1/en active Pending
- 2021-09-10 MX MX2023002852A patent/MX2023002852A/es unknown
- 2021-09-10 US US18/044,730 patent/US20230364230A1/en active Pending
- 2021-09-10 JP JP2023516079A patent/JP2023540618A/ja active Pending
- 2021-09-10 AU AU2021339005A patent/AU2021339005A1/en not_active Abandoned
- 2021-09-10 CN CN202180062423.4A patent/CN116601171A/zh active Pending
- 2021-09-10 KR KR1020237011801A patent/KR20230066586A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Crescioli et al. | Antibodies to watch in 2024 | |
| JP2020504723A5 (enExample) | ||
| CN105012953B (zh) | 用cd37-特异性和cd20-特异性结合分子减少b-细胞 | |
| Strohl | Structure and function of therapeutic antibodies approved by the US FDA in 2023 | |
| US12351639B2 (en) | Anti-CD30 antibodies | |
| JP2025138634A (ja) | Ｂ細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療 | |
| CN101420978B (zh) | 通过三官能双特异性抗体破坏表达低至中等水平的肿瘤相关靶抗原的肿瘤细胞 | |
| CN109963592B (zh) | Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| Smits et al. | Bispecific T-cell engagers (BiTEs) as treatment of B-cell lymphoma | |
| US20230197278A1 (en) | Multi-variate model for predicting cytokine release syndrome | |
| CN110461361A (zh) | 结合bcma、nkg2d和cd16的蛋白 | |
| EP3294769B1 (en) | Treatment for multiple myeloma (mm) | |
| CA3108646A1 (en) | Proteins binding nkg2d, cd16 and a tumor-associated antigen | |
| JP2020516309A5 (enExample) | ||
| US20220411512A1 (en) | Combination treatment for cancer | |
| US20210040213A1 (en) | Immunomonotherapy for urothelial carcinoma | |
| CN109134652A (zh) | Pan-ELR+ CXC 趋化因子抗体 | |
| US20250340634A1 (en) | Dosage regimens for anti-cd19 agents and uses thereof | |
| JP2023547506A5 (enExample) | ||
| JP7712925B2 (ja) | 腫瘍治療のための二重特異性融合タンパク質と抗Ｈｅｒ２抗体の組合せ | |
| Pandey et al. | Monoclonal antibodies as therapeutics in human malignancies | |
| JP2022537703A (ja) | 抗体および使用方法 | |
| Foster et al. | Treatment of hematological malignancies with T cell redirected bispecific antibodies: current status and future needs | |
| JP2023513434A5 (enExample) | ||
| JP2023540618A5 (enExample) |